OPDIVO® (nivolumab) in Combination with Chemotherapy as First-Line Therapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma as well as Unresectable Advanced or Metastatic Esophageal Squamous-Cell Carcinoma: Results from Checkmate 649 and Checkmate 648 Read More ›
